ArticleCellular and molecular bioengineering2025
Developing Nanoparticle-Based Therapeutics for Targeting the Microenvironment in Obesity-Induced Endometrial Cancer.
Article in Cellular and molecular bioengineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Integrin α7 defines a profibrotic adipose stromal population targeted for nanoparticle PAI-1 gene silencing in obesity.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- Application of nanoparticles in the therapeutic management of endometrial cancer.European journal of medical research · 2026Review
- Translational Progress of Inorganic Nanotheranostic Platforms for Gynecologic Malignancies: A Narrative Review of Endometrial, Ovarian, and Cervical Cancer Focusing on Fertility Preservation, Biosafety, and Industrial Translation.International journal of nanomedicine · 2026Review
- Rational design of immunogenic nanoparticles as a platform to reduce ovarian tumor burden in mice.International journal of pharmaceutics · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
11 authors.
Funding
Abstract
Background: The global rise of obesity has contributed to an increase in the incidence of endometrial cancer, the most common gynecologic malignancy. This obesity-driven increase, alongside limited therapeutic options, presents a growing public health concern. Our previous research indicated that adipose stem cells (ASCs), shed from fat depots, infiltrate the endometrium via the circulation in endometrial cancer patients with obesity. Furthermore, ASCs elicited the malignant transformation of endometrial epithelial cells (EECs) and fostered an oncogenic microenvironment driven by the plasminogen activator inhibitor 1 (PAI-1). Objective: To develop a nanoparticle-based system to deliver PAI-1 siRNA targeting the microenvironment of obesity-driven endometrial tumors. Methods: We developed 2D and 3D spheroid in vitro systems modeling the effects of endometrial microenvironment on ASCs to identify ASC integrin targeting markers. We also analyzed gonadal fat and uterine tissue from obese (ob/ob) mice, validating these ASC integrin markers in vivo. For targeted delivery, we engineered lipid-coated mesoporous silica nanoparticles (LCMSNs) loaded with PAI-1 siRNA. These nanoparticles were administered to ob/ob mice via intraperitoneal injection to evaluate targeting and therapeutic efficiency. Results: ASCs exposed to an oncogenic endometrial microenvironment showed increased integrin alpha 7 (ITGA7) and PAI-1 expression in vitro. Analysis of gonadal fat and uterine tissue from obese mice confirmed ITGA7 as a promising ASC targeting marker within the endometrial cancer microenvironment. LCMSNs conjugated with anti-ITGA7 antibody exhibited targeting capability toward ITGA7-positive ASCs. In obese mice, these LCMSNs showed strong uterine retention and effective PAI-1 silencing. Conclusion: Our findings demonstrate the potential of ITGA7-targeted LCMSNs as a PAI-1 siRNA delivery system to therapeutically target ASC-mediated oncogenesis in the endometrial tumor microenvironment. Future studies will evaluate the efficacy of PAI-1 silencing in inhibiting obesity-driven endometrial cancer growth, using in vivo models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.